弥合成本差距:比较美国兽医和人类皮肤病药物定价
Travis S Dowdle1, Madelyn Schmidt2, Nicole Remmert3
1Department of Dermatology, University of Texas Medical Branch, Galveston, Texas, USA.
概括
人类皮肤医学药物,特别是生物药物和Janus激酶 (JAK) 抑制剂,比兽医版本贵得多. 这种价格差异限制了患者获得关键治疗的机会,需要政策改革以提高透明度.
科学领域:
- 皮肤病学 皮肤病学
- 药物经济学 药物经济学
- 比较医学是一种比较医学.
背景情况:
- 高昂的药物成本,特别是新生物药和氏激酶 (JAK) 抑制剂,阻碍了获得皮肤病治疗的机会.
- 类似药物的兽医配方价格要便宜得多,这表明存在显著的价格差异.
研究的目的:
- 量化人类和兽医皮肤病药物之间的价格差异.
- 调查这些成本变化背后的潜在原因,重点关注生物药物和JAK抑制剂.
主要方法:
- 从GoodRx.com收集了人类皮肤病药物的定价数据.
- 来自VetrRx Direct,物VM和Chewy的兽医药物价格.
- 在各种药物类别中比较成本,包括抗生素,抗真菌药物,生物制剂和JAK抑制剂.
主要成果:
- 人类药物配方的平均价格是兽医配方的两倍.
- 生物制剂和JAK抑制剂的价格差异极大,在人体配方中成本高达71倍.
- 在多种皮肤病药物类别中观察到显著的成本差异.
结论:
- 与兽医同类药物相比,人类皮肤病药物的价格上是相当大的.
- 迫切需要药品定价透明度和政策改革,以应对过高的成本,特别是先进疗法.
- 解决这些差异可以改善患者获得基本皮肤病治疗的机会.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
230
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
230
Pharmaceutical Equivalents
177
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
177
Drug Nomenclature
3.2K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.2K
Bioequivalence: Overview
1.8K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.8K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
177
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
177
Bioequivalence of Drugs: Drugs with Multiple Indications
147
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
147


